Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
about
Challenges and opportunities for the implementation of virological testing in resource-limited settingsVirologic failure of protease inhibitor-based second-line antiretroviral therapy without resistance in a large HIV treatment program in South AfricaLong-term efficacy of first line antiretroviral therapy in Indian HIV-1 infected patients: a longitudinal cohort studyRates of switching antiretroviral drugs in a primary care service in South Africa before and after introduction of tenofovirTuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settingsHealthcare utilization of patients accessing an African national treatment program.Utility of CD4 cell counts for early prediction of virological failure during antiretroviral therapy in a resource-limited settingMonitoring virologic responses to antiretroviral therapy in HIV-infected adults in Kenya: evaluation of a low-cost viral load assayDurable HIV RNA resuppression after virologic failure while remaining on a first-line regimen: a cohort study.Deferred modification of antiretroviral regimen following documented treatment failure in Asia: results from the TREAT Asia HIV Observational Database (TAHOD).A cross-sectional study to evaluate second line virological failure and elevated bilirubin as a surrogate for adherence to atazanavir/ritonavir in two urban HIV clinics in Lilongwe, Malawi.Cost-effectiveness of HIV monitoring strategies in resource-limited settings: a southern African analysisTreatment interruption and variation in tablet taking behaviour result in viral failure: a case-control study from Cape Town, South Africa.Scale-up of a decentralized HIV treatment programme in rural KwaZulu-Natal, South Africa: does rapid expansion affect patient outcomes?Comparative effectiveness of HIV testing and treatment in highly endemic regions.Impact and programmatic implications of routine viral load monitoring in Swaziland.The impact of the 2013 WHO antiretroviral therapy guidelines on the feasibility of HIV population prevention trials.Monitoring of antiretroviral therapy and mortality in HIV programmes in Malawi, South Africa and Zambia: mathematical modelling studyValidating five questions of antiretroviral nonadherence in a public-sector treatment program in rural South AfricaHIV Suppression among Patients on Treatment in Vietnam: A Review of HIV Viral Load Testing in a Public Urban Clinic in Ho Chi Minh City.Virological breakthrough: a risk factor for loss to followup in a large community-based cohort on antiretroviral therapy.Persistent difficulties in switching to second-line ART in sub-saharan Africa--a systematic review and meta-analysis.Safety, Tolerability, and Efficacy of Second-Line Generic Protease Inhibitor Containing HAART after First-Line Failure among South Indian HIV-Infected Patients.Comparative effectiveness and cost-effectiveness of antiretroviral therapy and pre-exposure prophylaxis for HIV prevention in South AfricaThe cost-effectiveness of monitoring strategies for antiretroviral therapy of HIV infected patients in resource-limited settings: software toolDrug resistance patterns and virus re-suppression among HIV-1 subtype C infected patients receiving non-nucleoside reverse transcriptase inhibitors in South AfricaDried blood spots for viral load monitoring in Malawi: feasible and effectiveHIV type-1 clade C resistance genotypes in treatment-naive patients and after first virological failure in a large community antiretroviral therapy programmeEarly outcomes and the virological effect of delayed treatment switching to second-line therapy in an antiretroviral roll-out programme in South Africa.Assessing effectiveness and cost-effectiveness of concurrency reduction for HIV prevention.Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysisViral load monitoring and antiretroviral treatment outcomes in a pediatric HIV cohort in GhanaSuperior virologic and treatment outcomes when viral load is measured at 3 months compared to 6 months on antiretroviral therapyIs There a Need for Viral Load Testing to Assess Treatment Failure in HIV-Infected Patients Who Are about to Change to Tenofovir-Based First-Line Antiretroviral Therapy? Programmatic Findings from Myanmar.Cost Effectiveness of Potential ART Adherence Monitoring Interventions in Sub-Saharan Africa.Low-Cost Method to Monitor Patient Adherence to HIV Antiretroviral Therapy Using Multiplex Cathepsin ZymographyRate of initial highly active anti-retroviral therapy regimen change and its predictors among adult HIV patients at University of Gondar Referral Hospital, Northwest Ethiopia: a retrospective follow up studyEmerging antiretroviral drug resistance in sub-Saharan Africa: novel affordable technologies are needed to provide resistance testing for individual and public health benefits.Long-term virologic response and genotypic resistance mutations in HIV-1 infected Kenyan children on combination antiretroviral therapy.Outcomes of antiretroviral treatment in programmes with and without routine viral load monitoring in Southern Africa.
P2860
Q27026923-D4D7B0EA-B441-431E-8DFB-B281C04A3551Q28481468-765B07FC-7396-433E-BF55-BBE8E19232E6Q28485373-4B61D5CC-A2A4-4F68-A49C-C05E7360993AQ28533242-28EA01A4-1D62-48DE-8FA9-24D6D1AD8951Q28749315-74E63773-3A28-44F1-847C-E0F66FBDB14FQ33287043-7EDEBE65-74BD-4AB6-944A-3B1061C86C90Q33349204-F41E1EFB-083D-4B49-AD6A-6CC0335261B1Q33497943-CCBC1C52-8487-495A-8799-8FCEAB916A3AQ33805619-59C17D6F-5BA3-4AAD-8496-9C33575CB8B5Q33824851-95A2F31C-698E-4C25-A238-0E4BE8C00FBEQ33868639-195186E4-0E05-4084-B499-7B652EF7DE31Q33950833-EA0AAA11-4DE1-4903-8560-3C2D8C9B082FQ33999150-958E048F-8459-457A-830D-38BF9CD778BAQ34015581-FC6B5224-972B-44D3-9D8F-DB71862A3038Q34064269-44AE22EA-9963-47FE-8D6F-C7D34772C491Q34110897-2063C66E-8DCD-4409-BD9F-49BE978F7E95Q34418077-53AE564E-EA65-4768-AFC9-B7CD5820344EQ34612284-309A4DDC-9657-42DB-9546-BCD0B7AF5774Q34624904-D88DE751-20C2-4A93-9ED7-7BDF70CC471DQ34735495-247F8230-54A3-4093-8C42-FDC8070E0D9AQ35058006-D883AB5E-89D7-4231-BF61-BEA6DBC4B0C0Q35077695-2457505F-E8E4-4661-98F6-477697B1FA8DQ35083506-A5629085-628B-4C93-8618-95432FE79D95Q35120904-F1110146-9B70-4FDC-8357-48C8EEEED992Q35202699-A5448882-AE37-4811-ABB9-88571AFD131FQ35217629-9635C5C5-A2CD-4C92-AFC7-7817EA4889B7Q35515391-29FD261E-F99C-40A2-8539-D16F7E244103Q35536296-7BF1D3D7-E8D0-4387-9706-00FE5F8106ECQ35575725-3D1B6F7D-7D78-4448-8B6D-CF9A31410973Q35591286-07D9313A-2CA3-4CF6-893A-5CE9D146FD1DQ35847158-AB122F6C-A3A6-4E3D-AC29-939C2C258C77Q35914071-A3A24F47-3084-4FD2-8F95-56086B5FE18BQ36090721-1153064B-E6C7-4CB0-96F2-89E2E217A3D8Q36098892-BC5FC799-D0F0-4FEC-8311-EB9357BFC4A2Q36224801-739BCB3E-8379-463C-84A1-61C7FF0E7A33Q36460146-EF836793-9915-4CA5-A94E-C94FE017C156Q36587875-5BA5EE50-388B-451A-9882-6064084A99F4Q36669337-F199EFCC-975D-4933-BF87-07AF8EE23DF1Q36673503-9047D851-C0EA-4060-A84A-3189BAA72163Q36708737-69644CD5-3EE7-43A7-B1CA-8464245A431E
P2860
Conservation of first-line antiretroviral treatment regimen where therapeutic options are limited.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Conservation of first-line ant ...... erapeutic options are limited.
@en
Conservation of first-line ant ...... erapeutic options are limited.
@nl
type
label
Conservation of first-line ant ...... erapeutic options are limited.
@en
Conservation of first-line ant ...... erapeutic options are limited.
@nl
prefLabel
Conservation of first-line ant ...... erapeutic options are limited.
@en
Conservation of first-line ant ...... erapeutic options are limited.
@nl
P2093
P1433
P1476
Conservation of first-line ant ...... herapeutic options are limited
@en
P2093
Catherine Orrell
Linda-Gail Bekker
Matthew McNally
Richard Kaplan
Robin Wood
Stephen D Lawn
P50
P577
2007-01-01T00:00:00Z